Evaluating the Safety of Maribavir for the Treatment of Cytomegalovirus.

Published in: Therapeutics and clinical risk management (2022)

Maribavir provides a new agent for the management of resistant/refractory CMV infection. Results of the recently published phase 3 study provide further insight into the role of this novel therapy.

Keyphrases

open label
epstein barr virus
randomized controlled trial
stem cells
systematic review
clinical trial
combination therapy
mesenchymal stem cells
replacement therapy
meta analyses